Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Contralateral second dose improves antibody responses to a 2-dose mRNA vaccination regimen

Journal of Clinical Investigation(2024)10.1172/jci176411Source: DataRank Database

Contralateral second dose improves antibody responses to a 2-dose mRNA vaccination regimen is a research paper published in Journal of Clinical Investigation (2024). On theSindex it has a DataRank of 0. It has been cited 17 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access17 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (8 grants)Impact (FWCI 2.72)OA: goldTopics (44)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (10)

Archana Thomas ORCID,Abram E. Estrada,Hiro A.P. Ross,David X. Lee ORCID,Steven C. Kazmierczak ORCID

Live enrichment

PubMed:38227381 PMC:PMC10940087 OpenAlex:https://openalex.org/W4390919658

NIH / NIAID

Grant: 1R01AI145835

R.J. Murdock Charitable Trust

Grant: 202015613

NCATS NIH HHS

Grant: UL1 TR002369

NIAID NIH HHS

Grant: R01 AI145835

NIH HHS

Grant: P51 OD011092

National Institutes of Health

Grant: 5R01AI145835-04

Long Term Immunity Following Yellow Fever Vaccination

National Institutes of Health

Grant: 3P51OD011092-55S1

SUPPORT FOR NATIONAL PRIMATE RESEARCH CENTER

National Institutes of Health

Grant: 3UL1TR002369-04S2

Oregon Clinical and Translational Research Institute - The National COVID Cohort Collaborative (N3C)

FWCI

2.72

Citation Percentile

0.9%

Citation Trend

2024

2025

2026

goldLicense: cc-by

journalhttp://www.jci.org/articles/view/176411/files/pdf

publisherhttp://www.jci.org/articles/view/176411/files/pdf

publisherhttps://www.jci.org/articles/view/176411/files/pdf

journalhttps://doi.org/10.1172/jci176411

repositoryhttps://pubmed.ncbi.nlm.nih.gov/38227381

Fields of Study

RNA Interference and Gene DeliveryMonoclonal and Polyclonal Antibodies ResearchImmunotherapy and Immune Responses0303 health sciences03 medical and health sciencesAdultHumansAntibody FormationCOVID-19 VaccinesBNT162 VaccineVaccinationAntibodies, ViralImmunoglobulin GRNA, MessengerAntibodies, Neutralizing

MeSH Terms

COVID-19 VaccinesBNT162 VaccineAdultAntibodies, ViralAntibody FormationHumansImmunoglobulin GRNA, MessengerVaccinationAntibodies, Neutralizing

Keywords

VaccinationRegimenMedicineAntibodyImmune systemImmunologyInternal medicineInfectious diseaseadaptive immunityAdultCOVID-19 VaccinesImmunoglobulin GAntibody FormationHumansRNA, MessengerClinical MedicineAntibodies, ViralAntibodies, NeutralizingBNT162 Vaccine

Sustainable Development Goals

SDG 0: Good health and well-being

Related Papers (2)

Multivalent S2-based vaccines provide broad protection against SARS-CoV-2 variants of concern and pangolin coronaviruses

EBioMedicine(2022)

co-cited

10.1016/j.ebiom.2022.104341

Longitudinal dynamics of the human B cell response to the yellow fever 17D vaccine

N/A

3.9DataRank · unranked

Proceedings of the National Academy of Sciences(2020)

co-cited

10.1073/pnas.1921388117